Unit dosage of Apadenoson

Patent metadata

Field	Value
Publication number	US-9415058-B2
Application number	US-201314103130-A
Country	US
Kind code	B2
Filing date	Dec 11, 2013
Priority date	Jul 3, 2008
Publication date	Aug 16, 2016
Grant date	Aug 16, 2016

Abstract

The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.

First claim

What is claimed is:

1. A method of chemically inducing stress and diagnosing myocardial perfusion abnormalities in a mammal, comprising:
(a) selecting a dose of Apadenoson between about 100-175 μg on a basis that is independent of the weight of the mammal to whom the dose will be administered;
(b) administering to said mammal, via bolus, the dose of Apadenoson as a unit dose comprising Apadenson and a pharmaceutically acceptable carrier; and
(c) performing a technique to detect the presence of coronary artery stenoses in the mammal, to assess the severity of coronary artery stenoses in the mammal, or a combination thereof, so as to diagnose myocardial perfusion abnormalities in said mammal.

2. The method of claim 1 , wherein the unit dose further contains an effective amount of β-hydroxypropyl-cyclodextrin (HP-β-CD).

3. The method of claim 2 , wherein the amount of HP-β-CD is about 0.1-10% w/v of the final formulation.

4. The method of claim 2 , wherein the amount of HP-β-CD is 1% w/v.

5. The method of claim 1 , wherein the dose of Apadenoson is 100 μg.

6. The method of claim 1 , wherein the dose of Apadenoson is 150 μg.

7. The method of claim 1 , wherein the unit dose is 1 mL in volume.

8. The method of claim 1 , wherein the unit dose is 2 mL in volume.

9. The method of claim 1 , wherein the unit dose is 3 mL in volume.

10. The method of claim 1 , wherein the unit dose is 4 mL in volume.

11. The method of claim 1 , wherein the unit dose is 5 mL in volume.

12. The method of claim 1 , wherein the dose of Apadenoson is selected on the basis of a single weight of Apadenoson being effective in previously tested mammals having a range of different weights.

13. The method of claim 1 , wherein the unit dose further contains sodium citrate buffer.

14. The method of claim 13 , wherein sodium citrate buffer is present in an amount to buffer the unit dose to pH selected from 4.6-5.0.

15. The method of claim 1 , wherein the dose of Apadenoson is 175 μg.

Assignees

• Univ Virginia Patent Foundation

Inventors

• Hendel Robert
• Stilley William B
• Williams Shannon P

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61K9/0019 Primary

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K47/02

  Inorganic compounds · CPC title

• A61K47/40

  Cyclodextrins; Derivatives thereof · CPC title